Creo Medical Group (LON:CREO) Issues Earnings Results

Creo Medical Group (LON:CREO) announced its quarterly earnings results on Wednesday. The company reported GBX (2) earnings per share for the quarter, Digital Look Earnings reports. Creo Medical Group had a net margin of 88.33% and a return on equity of 9.56%.

Creo Medical Group Stock Performance

LON:CREO opened at GBX 10.40 on Thursday. The stock has a market cap of £50.52 million, a P/E ratio of 10.40 and a beta of 1.56. The firm’s fifty day simple moving average is GBX 12.70 and its 200 day simple moving average is GBX 12.85. Creo Medical Group has a twelve month low of GBX 9.52 and a twelve month high of GBX 18.50. The company has a quick ratio of 2.19, a current ratio of 3.22 and a debt-to-equity ratio of 8.20.

Analysts Set New Price Targets

Separately, Shore Capital Group restated a “house stock” rating and issued a GBX 40 price objective on shares of Creo Medical Group in a research report on Thursday, July 23rd.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.